^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Melanoma |
| Drug: | everolimus (mTOR inhibitor) + dichloroacetate topical (PDK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
Published date:
05/24/2021
Excerpt:
The BRAFV600E -vemurafenib resistant melanoma cell line showed to retain sensitivity to both everolimus and DCA.
DOI:
10.2147/JEP.S297831
